INS and diabetes mellitus: In 2012–2019, second‐generation insulin analogues (insulin degludec and glargine U300 [Gla‐300]) and many noninsulin diabetes medications (such as dipeptidyl peptidase‐4 [DPP‐4] inhibitors, sodium‐glucose linked transporter‐2 [SGLT2] inhibitors, and glucagon‐like peptide‐1 [GLP‐1] analogues) became available.6